Gilead Sciences, Inc. to Acquire Pharmasset, Inc. for $11 Billion
by RealPTC Expert
Gilead Sciences, Inc. and Pharmasset, Inc. announced on 21st November that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash. The transaction, which values Pharmasset at approximately $11 billion, was unanimously approved by Pharmasset’s Board of Directors. Gilead plans to finance the transaction with cash on hand, bank debt and senior unsecured notes. The company expects the transaction, when completed, to be dilutive to Gilead’s earnings through 2014 and accretive in 2015 and beyond. Further guidance will be provided when the transaction closes, which is expected to be in the first quarter of 2012.
Subscribe to:
Post Comments (Atom)
0 comments:
Leave a Comment